Skip to main content

Advertisement

SpringerLink
Log in

Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The approval of two new tyrosine kinase (TK) inhibitors, nilotinib and dasatinib, has raised the issue of cross-intolerance. Evaluating the safety of interchanging TK inhibitors is particularly important for patients who are intolerant to one medication but are considered to be sensitive to the other. Available data are limited and it is unclear whether switching between TK inhibitors is possible without an off-drug period. We present two patients with chronic myelogenous leukemia in whom, following the development of symptomatic pleural effusion, medications were safely switched from dasatinib to nilotinib after a 1-month off-drug period. The lymphocytosis and increased large granular lymphocyte count observed during dasatinib treatment also subsided after switching medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Giles FJ. New directions in the treatment of imatinib failure and/or resistance. Semin Hematol. 2009;46:S27–33.

    Article  CAS  PubMed  Google Scholar 

  2. Garg RJ, Kantarjian H, O’Brien S, Quintas-Cardama A, Faderi S, Estrov Z, et al. The use of nilotinib or dasatinib after failure to two prior tyrosine kinase inhibitors (TKI): long-term follow-up. Blood. 2009;114:4361–8.

    Article  CAS  PubMed  Google Scholar 

  3. Quintas-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3903–14.

    Article  Google Scholar 

  4. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99–105.

    Article  PubMed  Google Scholar 

  5. Yamamoto M, Kakihana K, Ohashi K, Yamaguchi T, Tadokoro K, Akiyama H, et al. Serial monitoring of T315I BCR-ABL mutation by invader assay combined with RT-PCR. Int J Hematol. 2009;89:482–8.

    Article  CAS  PubMed  Google Scholar 

  6. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–6.

    Article  CAS  PubMed  Google Scholar 

  7. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and–intolerant chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2008;26:3204–12.

    Article  CAS  PubMed  Google Scholar 

  8. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398–405.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Division, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan

    Yasunobu Nagata, Takeshi Kobayashi, Takuya Yamashita, Kazuteru Ohashi, Hisashi Sakamaki & Hideki Akiyama

  2. Laboratory Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

    Shiomi Fukuda

Authors
  1. Yasunobu Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiomi Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuya Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuteru Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hisashi Sakamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideki Akiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Akiyama.

About this article

Cite this article

Nagata, Y., Fukuda, S., Kobayashi, T. et al. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. Int J Hematol 91, 539–541 (2010). https://doi.org/10.1007/s12185-010-0526-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0526-8

Keywords

Search

Navigation